Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sEphB4-HSA in Genitourinary Cancers
NCT02767921Phase 1Terminated
- Sponsor
- University of Southern California
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sephb4-hsa in bladder urothelial carcinoma, prostate cancer (PCa) and renal cell carcinoma (RCC), sponsored by University of Southern California. Primary endpoints: Feasibility of treatment and Incidence of adverse events. Started Aug 2016; status: terminated.
02
Drugs
sephb4-hsa
03
Conditions
bladder urothelial carcinomaprostate cancer (PCa)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02767921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767921.